Asia Pacific Anti-Viral Therapies Market is expected to reach US$ 16,118.52 Mn by 2027

Branded Drugs Segment Held Larger Share of Anti-Viral Therapies Market in 2019

According to our new market research study on “Asia Pacific Anti-Viral Therapies Market to 2027 – Regional Analysis and Forecast – by Type, Mechanism of Action, and Application,” the market is expected to reach US$16,118.52 million by 2027 from US$ 8,135.93 million in 2019; it is estimated to grow at a CAGR of 9.0% from 2020 to 2027. The report provides trends prevailing in the Asia Pacific anti-viral therapies market, and drivers and restraints pertaining to the market growth.

In 2019, the branded drugs segment accounted for a larger share of the Asia Pacific anti-viral therapies market. The branded antiviral drugs are more trusted than the generic drugs. Further, robust research and development activities, increasing number of drug discoveries, and rising number of patents for drugs are the factors supporting the growth of this segment.

The growth of the Asia Pacific anti-viral therapies market is mainly attributed to the growing prevalence of viral diseases. Additionally, the availability of advanced therapeutic platforms for viral diseases and awareness programs to eradicate flu, Chikungunya, and Japanese encephalitis (JE), among other viral diseases, are further projected to drive Asia Pacific anti-viral therapies market during the forecast period. Further, the constantly developing healthcare sector is also anticipated to drive the growth of the market in developing economies such as India, China, Australia, and Malaysia. However, the high cost of drug development is a major factor hindering the market growth in Asia Pacific.

Aurobindo Pharma Ltd; AbbVie Inc.; GlaxoSmithKline plc; AstraZeneca; and F. HOFFMANN-LA ROCHE LTD are among the leading companies operating in the Asia Pacific anti-viral therapies market.

Asia Pacific Anti-Viral Therapies Market, by Country, 2019 (%)

---

Asia Pacific Anti-Viral Therapies Market to Grow at a CAGR of 9.0% to reach US$ 16,118.52 Million from 2020 to 2027

Download Free Sample

---

Asia Pacific Anti-Viral Therapies Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Type (Generic Drugs and Branded Drugs), Mechanism of Action (Nucleotide Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, and Others), and Application (HIV, Hepatitis, Virus Influenza, Herpes, and Other Applications), and Country

The Report Segments Asia Pacific Anti-Viral Therapies Market as Follows:

Asia Pacific Anti-Viral Therapies Market – by Type

• Branded Drugs
• Generic Drugs

Asia Pacific Anti-Viral Therapies Market – by Mechanism of Action

• Nucleotide Polymerase Inhibitors
• Reverse Transcriptase Inhibitors
• Protease Inhibitors
• Others

Asia Pacific Anti-Viral Therapies Market – by Application

• HIV
• Hepatitis
• Virus Influenza
• Herpes
• Others

Asia Pacific Anti-Viral Therapies Market – by Country

• China
• Japan
• India
• South Korea
• Australia